Mawer Investment Management Ltd. Has $115.82 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Mawer Investment Management Ltd. trimmed its stake in Becton, Dickinson and Company (NYSE:BDX) by 10.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 480,387 shares of the medical instruments supplier’s stock after selling 56,228 shares during the quarter. Mawer Investment Management Ltd. owned about 0.17% of Becton, Dickinson and Company worth $115,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC increased its holdings in shares of Becton, Dickinson and Company by 843.7% in the first quarter. Acadian Asset Management LLC now owns 3,237 shares of the medical instruments supplier’s stock worth $799,000 after purchasing an additional 2,894 shares during the period. UniSuper Management Pty Ltd increased its position in shares of Becton, Dickinson and Company by 225.9% during the first quarter. UniSuper Management Pty Ltd now owns 7,775 shares of the medical instruments supplier’s stock valued at $1,924,000 after acquiring an additional 5,389 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Becton, Dickinson and Company by 5.4% during the 1st quarter. Bessemer Group Inc. now owns 29,382 shares of the medical instruments supplier’s stock worth $7,272,000 after acquiring an additional 1,513 shares during the last quarter. Arjuna Capital boosted its stake in shares of Becton, Dickinson and Company by 3.8% during the 1st quarter. Arjuna Capital now owns 9,757 shares of the medical instruments supplier’s stock worth $2,414,000 after acquiring an additional 359 shares during the last quarter. Finally, Lake Street Advisors Group LLC boosted its stake in shares of Becton, Dickinson and Company by 19.6% during the 1st quarter. Lake Street Advisors Group LLC now owns 1,789 shares of the medical instruments supplier’s stock worth $443,000 after acquiring an additional 293 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded up $0.37 during mid-day trading on Monday, reaching $225.52. 25,832 shares of the company were exchanged, compared to its average volume of 1,404,169. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The company has a fifty day moving average of $236.30 and a 200 day moving average of $235.00. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a market cap of $65.18 billion, a PE ratio of 37.90, a PEG ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the business earned $3.42 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Analyst Ratings Changes

A number of research firms recently commented on BDX. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James reduced their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.